These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19169488)

  • 1. Recurrence of papillary thyroid cancer suspected by high anti-thyroglobulin antibody levels and detection of peripheral blood thyroglobulin mRNA.
    Coelho SM; Buescu A; Corbo R; Carvalho DP; Vaisman M
    Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1321-5. PubMed ID: 19169488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thyroglobulin mRNA amplification in peripheral blood of patients with differentiated thyroid carcinoma: what does it really mean?].
    Coelho SM; Vaisman M; de Carvalho DP
    Arq Bras Endocrinol Metabol; 2006 Jun; 50(3):427-35. PubMed ID: 16936982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
    Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
    Milas M; Barbosa GF; Mitchell J; Berber E; Siperstein A; Gupta M
    Ann Surg Oncol; 2009 Feb; 16(2):473-80. PubMed ID: 19015922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer.
    Grammatopoulos D; Elliott Y; Smith SC; Brown I; Grieve RJ; Hillhouse EW; Levine MA; Ringel MD
    Mol Pathol; 2003 Jun; 56(3):162-6. PubMed ID: 12782763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating epithelial cells as potential biomarkers for detection of recurrence in patients of papillary thyroid carcinoma with positive serum anti-thyroglobulin antibody.
    Li YR; Tseng CP; Hsu HL; Lin HC; Chen YA; Chen ST; Liou MJ; Lin JD
    Clin Chim Acta; 2018 Feb; 477():74-80. PubMed ID: 29229463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting Recurrence Following Lobectomy for Thyroid Cancer: Role of Thyroglobulin and Thyroglobulin Antibodies.
    Ritter A; Mizrachi A; Bachar G; Vainer I; Shimon I; Hirsch D; Diker-Cohen T; Duskin-Bitan H; Robenshtok E
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32219303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
    Denizot A; Delfino C; Dutour-Meyer A; Fina F; Ouafik L
    Thyroid; 2003 Sep; 13(9):867-72. PubMed ID: 14588101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
    Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
    Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.
    Mousa U; Yikilmaz AS; Nar A
    Clin Transl Oncol; 2017 Aug; 19(8):1028-1034. PubMed ID: 28258491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does undetectable basal Tg measured with a highly sensitive assay in the absence of antibodies and combined with normal ultrasonography ensure the absence of disease in patients treated for thyroid carcinoma?
    Rosário PW; Mineiro Filho AF
    Arq Bras Endocrinol Metabol; 2012 Mar; 56(2):149-51. PubMed ID: 22584569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroglobulin: current status in differentiated thyroid carcinoma (review).
    Harish K
    Endocr Regul; 2006 Jun; 40(2):53-67. PubMed ID: 17100547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum thyroglobulin antibody levels as a dynamic prognostic factor for early-phase recurrence of thyroglobulin antibody-positive papillary thyroid carcinoma after total thyroidectomy.
    Yamada O; Miyauchi A; Ito Y; Nakayama A; Yabuta T; Masuoka H; Fukushima M; Higashiyama T; Kihara M; Kobayashi K; Miya A
    Endocr J; 2014; 61(10):961-5. PubMed ID: 25029954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowered cutoff of lymph node fine-needle aspiration thyroglobulin in thyroid cancer patients with serum anti-thyroglobulin antibody.
    Jo K; Kim MH; Lim Y; Jung SL; Bae JS; Jung CK; Kang MI; Cha BY; Lim DJ
    Eur J Endocrinol; 2015 Oct; 173(4):489-97. PubMed ID: 26208979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer.
    Eszlinger M; Neumann S; Otto L; Paschke R
    Eur J Endocrinol; 2002 Nov; 147(5):575-82. PubMed ID: 12444888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood.
    Ringel MD; Ladenson PW; Levine MA
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4435-42. PubMed ID: 9851791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of recurrent thyroid cancer by sensitive nested reverse transcription-polymerase chain reaction of thyroglobulin and sodium/iodide symporter messenger ribonucleic acid transcripts in peripheral blood.
    Biscolla RP; Cerutti JM; Maciel RM
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3623-7. PubMed ID: 11061512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recurrence of differentiated thyroid carcinoma without concomitant elevation of serum thyroglobulin: report of two cases].
    Velasco S; Solar A; Cruz F; Quintana JC; León A; Mosso L; Fardella C
    Rev Med Chil; 2007 Apr; 135(4):506-11. PubMed ID: 17554461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.